C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients

Journal of Human Hypertension

Volumn 20, Issue 8, 2006, Pages 587-592

  Conen, D ^a   Zeller, A ^a   Dieterle, T ^a   Martina, B ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANAMNESIS; ARTICLE; CLASSIFICATION; CLINICAL EXAMINATION; ECHOCARDIOGRAPHY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT CARE; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT;

C-REACTIVE PROTEIN; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33746257173     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002048     Document Type: Article

References (31)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
3. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761-767.
4. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM): Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128-2136.
5. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
6. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987-1003.
7. 9 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-183.
8. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
9. Schillaci G, de Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P. Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 2002; 20: 1519-1525.
10. Cuspidi C, Michev L, Severgnini B, Meani S, Fusi V, Valerio C et al. Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives. J Hum Hypertens 2003; 17: 101-106.
11. Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Severgnini B et al. Cardiovascular risk stratification in hypertensive patients: Impact of echocardiography and carotid ultrasonography. J Hypertens 2001; 19: 375-380.
12. Martinez MA, Sancho T, Armada E, Rubio JM, Anton JL, Torre A et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: Impact of echocardiography on cardiovascular risk stratification. Am J Hypertens 2003; 16: 556-563.
13. Luque M, de Rivas B, Alvarez B, Garcia G, Fernandez C, Martell N. Influence of target organ lesion detection (assessment of microalbuminuria and echocardiogram) in cardiovascular risk stratification and treatment of untreated hypertensive patients. J Hum Hypertens 2006; 20: 187-192.
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
15. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391-397.
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
17. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625-1632.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
19. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-1959.
20. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO et al. C-reactive protein modifies the relationship between blood pressure and micro-albuminuria. Hypertension 2004; 43: 791-796.
21. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
22. Conen D, Zeller A, Pfisterer M, Martina B. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006; 97: 249-252.
23. Leoncini G, Sacchi G, Ravera M, Viazzi F, Ratto E, Vettoretti S et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16: 399-404.
24. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E et al. Microalbuminuria identifies overall cardiovascular risk in essential hypertension: An artificial neural network-based approach. J Hypertens 2002; 20: 1315-1321.
25. Tsioufis C, Dimitriadis K, Antoniadis D, Stefanadis C, Kallikazaros I. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004; 17: 470-476.
26. Ferrara LA, Vaccaro O, Cardoni O, Laurenzi M, Mancini M, Zanchetti A. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 2005; 18: 1282-1287.
27. Wong ND, Pio J, Valencia R, Thakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 2001; 4: 109-114.
28. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509-1515.
29. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino Jr RB, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46: 1869-1874.
30. Xie X, Liu K, Stamler J, Stamler R. Ethnic differences in electrocardiographic left ventricular hypertrophy in young and middle-aged employed American men. Am J Cardiol 1994; 73: 564-567.
31. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: The Dallas Heart Study. Hypertension 2005; 46: 124-129.